DDInter596 DDInter1825
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Miconazole
Miconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) IL13RA1
IL13RA1 {u} (Gene) is upregulated by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) IL13RA1
IL13RA1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may lead to a major life threatening interaction when taken with Tofacitinib
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Doxorubicin (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Doxorubicin (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Miconazole (Compound) and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Doxorubicin (Compound) upregulates IL13RA1 (Gene) and IL13RA1 (Gene) is upregulated by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Doxorubicin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Doxorubicin (Compound) upregulates IL13RA1 (Gene) and IL13RA1 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Doxorubicin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib